Baxter International Inc. (BAX): Price and Financial Metrics

Baxter International Inc. (BAX): $86.70

-0.74 (-0.85%)

POWR Rating

Component Grades














  • Value is the dimension where BAX ranks best; there it ranks ahead of 89.69% of US stocks.
  • BAX's strongest trending metric is Value; it's been moving up over the last 198 days.
  • BAX's current lowest rank is in the Momentum metric (where it is better than 15.12% of US stocks).

BAX Stock Summary

  • BAX has a market capitalization of $43,597,267,793 -- more than approximately 94.27% of US stocks.
  • Baxter International Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.94% of US equities in our set.
  • The volatility of Baxter International Inc's share price is greater than that of merely 0.73% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to BAX, based on their financial statements, market capitalization, and price volatility, are TEL, IDXX, KLAC, DHI, and ZBH.
  • BAX's SEC filings can be seen here. And to visit Baxter International Inc's official web site, go to

BAX Price Target

For more insight on analysts targets of BAX, see our BAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $92.06 Average Broker Recommendation 1.53 (Moderate Buy)

BAX Stock Price Chart Interactive Chart >

Price chart for BAX

BAX Price/Volume Stats

Current price $86.70 52-week high $91.58
Prev. close $87.44 52-week low $74.79
Day low $86.42 Volume 1,958,700
Day high $86.90 Avg. volume 2,646,401
50-day MA $82.87 Dividend yield 1.13%
200-day MA $81.21 Market Cap 43.60B

Baxter International Inc. (BAX) Company Bio

Baxter International provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products and anesthetics, and pharmacy automation, software and services. The company was founded in 1931 and is based in Deerfield, Illinois.

BAX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$86.70$26.28 -70%

Below please find a table outlining a discounted cash flow forecast for BAX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Baxter International Inc ranked in the 27th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 69.5%. The most interesting components of our discounted cash flow analysis for Baxter International Inc ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 9.54; that's higher than 62.96% of US stocks in the Healthcare sector that have positive free cash flow.
  • BAX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 26.37% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

BSX, CPIX, GILD, HSIC, and INFU can be thought of as valuation peers to BAX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

BAX Latest News Stream

Event/Time News Detail
Loading, please wait...

BAX Latest Social Stream

Loading social stream, please wait...

View Full BAX Social Stream

Latest BAX News From Around the Web

Below are the latest news stories about Baxter International Inc that investors may wish to consider to help them evaluate BAX as an investment opportunity.

Baxter to Present at the UBS Global Healthcare Virtual Conference

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 2:00 p.m. Eastern Time.

Yahoo | May 4, 2021

Leerink Partners Stick to Their Buy Rating for Baxter International By

Leerink Partners Stick to Their Buy Rating for Baxter International | May 3, 2021

Baxter Increases Dividend and Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced an increase in the company’s quarterly cash dividend to a rate of $0.28 per share of common stock. This represents an approximately 14% increase over the previous quarterly dividend rate of $0.245 per share. Baxter’s Board of Directors declared the dividend payable on July 1, 2021, to stockholders of record as of June 4, 2021. The indicated annual dividend rate is now $1.12 per share of common stock.

Yahoo | May 3, 2021

Baxter International Inc. 2021 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Baxter International Inc. in conjunction with their 2021 Q1 earnings call....

SA Transcripts on Seeking Alpha | April 29, 2021

Medical Products' Apr 29 Earnings Roster: TMO, BAX & More

The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.

Yahoo | April 28, 2021

Read More 'BAX' Stories Here

BAX Price Returns

1-mo 2.10%
3-mo 12.51%
6-mo 10.54%
1-year -0.21%
3-year 27.42%
5-year 103.13%
YTD 8.39%
2020 -2.95%
2019 28.40%
2018 2.89%
2017 47.30%
2016 17.58%

BAX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full BAX Dividend History

Continue Researching BAX

Want to see what other sources are saying about Baxter International Inc's financials and stock price? Try the links below:

Baxter International Inc (BAX) Stock Price | Nasdaq
Baxter International Inc (BAX) Stock Quote, History and News - Yahoo Finance
Baxter International Inc (BAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7755 seconds.